Key points are not available for this paper at this time.
PIV is a robust prognostic marker for lung cancer, reliably predicting both OS and PFS. It offers valuable insights across various treatment strategies, including immunotherapy, and could enhance clinical decision-making by providing a cost-effective and reliable tool for evaluating patient prognosis.
Hong et al. (Mon,) studied this question.